4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
AbCellera Biologics Inc. (ABCL) operates in the Biotechnology industry and is headquartered in Vancouver, Canada with about 562 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, ABCL reported $75M in revenue and ($146M) in net income.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
Interactive charts & full statements → Open the ABCL valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $75M | $29M | $38M | $485M | — |
| Gross Profit | — | $29M | $38M | $419M | $330M |
| Operating Income (EBIT) | ($203M) | ($301M) | ($223M) | $227M | — |
| Net Income | ($146M) | ($163M) | ($146M) | $158M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $8M | $45M | $9M | $17M | $4M | — |
| Operating Income (EBIT) | ($53M) | ($25M) | ($74M) | ($46M) | ($58M) | — |
| Net Income | ($43M) | ($9M) | ($57M) | ($35M) | ($46M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $1.4B | $1.4B | $1.5B | $1.5B | — |
| Total Liabilities | $390M | $304M | $336M | $308M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ABCL viewer.
About TickerBase · Data methodology & sources